EFFEXOR Drug Patent Profile
✉ Email this page to a colleague
When do Effexor patents expire, and when can generic versions of Effexor launch?
Effexor is a drug marketed by Wyeth Pharms Inc and Upjohn and is included in two NDAs.
The generic ingredient in EFFEXOR is venlafaxine hydrochloride. There are seventy-one drug master file entries for this compound. Sixty-six suppliers are listed for this compound. Additional details are available on the venlafaxine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Effexor
A generic version of EFFEXOR was approved as venlafaxine hydrochloride by TEVA on August 3rd, 2006.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EFFEXOR?
- What are the global sales for EFFEXOR?
- What is Average Wholesale Price for EFFEXOR?
Summary for EFFEXOR
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 224 |
| Clinical Trials: | 63 |
| Patent Applications: | 2,087 |
| Drug Prices: | Drug price information for EFFEXOR |
| Drug Sales Revenues: | Drug sales revenues for EFFEXOR |
| What excipients (inactive ingredients) are in EFFEXOR? | EFFEXOR excipients list |
| DailyMed Link: | EFFEXOR at DailyMed |
Recent Clinical Trials for EFFEXOR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mit Ghamr Oncology Center | Phase 4 |
| Vanderbilt University Medical Center | Phase 4 |
| AbbVie | Phase 4 |
Paragraph IV (Patent) Challenges for EFFEXOR
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| EFFEXOR | Tablets | venlafaxine hydrochloride | 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg | 020151 | 1 | 2005-11-03 |
US Patents and Regulatory Information for EFFEXOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Pharms Inc | EFFEXOR | venlafaxine hydrochloride | TABLET;ORAL | 020151-001 | Dec 28, 1993 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Upjohn | EFFEXOR XR | venlafaxine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020699-001 | Oct 20, 1997 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Wyeth Pharms Inc | EFFEXOR | venlafaxine hydrochloride | TABLET;ORAL | 020151-003 | Dec 28, 1993 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EFFEXOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Wyeth Pharms Inc | EFFEXOR | venlafaxine hydrochloride | TABLET;ORAL | 020151-002 | Dec 28, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Wyeth Pharms Inc | EFFEXOR | venlafaxine hydrochloride | TABLET;ORAL | 020151-003 | Dec 28, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Wyeth Pharms Inc | EFFEXOR | venlafaxine hydrochloride | TABLET;ORAL | 020151-001 | Dec 28, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EFFEXOR
See the table below for patents covering EFFEXOR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Slovakia | 281530 | ⤷ Sign Up | |
| Ukraine | 77145 | EXTENDED RELEASE DOSAGE FORMULATION | ⤷ Sign Up |
| Poland | 341141 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for EFFEXOR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0112669 | 96C0002 | Belgium | ⤷ Sign Up | PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
